Kolexia
Schmitt Anna Oncologie hémato.
Schmitt Anna
Oncologie hémato.
Institut Bergonié
Bordeaux, France
98 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Récidive tumorale locale Tumeurs du système nerveux central Leucémies Maladie de Hodgkin Lymphome B diffus à grandes cellules Myélome multiple Leucémie myéloïde Leucémie myéloïde chronique BCR-ABL positive

Collaborateurs

Voir plus
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Houot Roch
Houot Roch
Hôpital Pontchaillou, Rennes, France
Adiko Didier
Adiko Didier
Centre Hospitalier Libourne, Libourne, France
Soussain Carole
Soussain Carole
Institut Curie, Saint-Cloud, France

Industries

Voir plus
Janssen
17 collaboration(s)
Dernière en 2023
Abbvie
2 collaboration(s)
Dernière en 2023
Sanofi
2 collaboration(s)
Dernière en 2022
Kappa Santé
1 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
Haematologica   30 novembre 2023
Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study.
Haematologica   01 octobre 2023
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma
Essai Clinique (Epizyme, Inc.)   03 août 2023
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in elderly mantle cell lymphoma patients. For the LYSA group.
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 ‐ 17 June, 2023   09 juin 2023
Systemic relapses of primary CNS lymphomas (PCNSL): a LOC network study.
Annals of hematology   29 mars 2023
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older: Phase II, Open-Label Study Evaluating Efficacy of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
Essai Clinique (The Lymphoma Academic Research Organisation)   16 mars 2023
A New Option for Pain Prevention Using a Therapeutic Virtual Reality Solution for Bone Marrow Biopsy (REVEH Trial): Open-Label, Randomized, Multicenter, Phase 3 Study.
Journal of medical Internet research   15 février 2023
Molecular and clinical diversity in primary central nervous system lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology   17 novembre 2022
What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
Annual Meeting Abstracts 2022   15 novembre 2022